All News
Inflammatory bowel disease in spondyloarthritis - does it matter?
Do the clinical features of axSpA patients with and without IBD differ?
In Abstract OP0085 at #EULAR2024, De Hooge M et al presented data from the METEOR cohort that identify clinical differences between these two groups. This will be important in order to stratify the management approach in axSpA patients with or without IBD as the emerging therapies have different effects on EMMs.
Reassessment of the cut-off values for ASDAS disease activity states in a large, multinational cohort of axSpA patients resulted in cut-offs largely similar to the currently endorsed cut-offs of 1.3, 2.1 and 3.5. Cut-off values between ID and LDA and between LDA and HDA, however,… https://t.co/vECCsmTggW https://t.co/XU7BQBYBdQ
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
New validated BASDAI cut offs. BASDAI values of <2, <4 and >6 are often applied as cut-offs between remission, low (LDA), high (HDA) and very high (VHDA) disease activity, respectively, although this remains unvalidated. The optimal BASDAI values against external criteria were… https://t.co/5cvWoddHaN https://t.co/oBwYmFsIga
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
EULAR Abstract Archive
POS0894 (2024)
SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa
Retrospective study in French THIN database
Diagnostic delay remains common
Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
From the Be-GIANT cohort, 44.3% of patients met the definition of early axSpA (<2 year symptom). The early axSpA group had younger age and lower frequency of radiographic sacroiliitis. Baseline characteristics and disease activity scores at baseline were similar. Physicians… https://t.co/6stDw8sHiI https://t.co/fjINAc4mw3
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
THE ASSOCIATION BETWEEN DEPRESSION AND BIOLOGIC PRESCRIBING IN AXIAL SPONDYLOARTHRITIS (axSpA): LESSONS FROM AN IRISH axSpA COHORT more likely to have peripheral arthritis enthesitis psoriasis - shoukd we be formally assessing eg Beck’s DI @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
MINIMAL SPINAL RADIOGRAPHIC PROGRESSION in RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS OVER 2 YEARS OF BIMEKIZUMAB TREATMENT: RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY - 90% nonprogressers on Bime including how many would never have progressed ? @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA
Results from a large population-based study show reassuring data, with no increased risk of #CVD, #VTE or certain cancers compared to TNFi or IL-17i
@SteZhao @RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at #EULAR2024 in Vienna, Austria:
OP0195
LBA0005
POS0803
OP0138
https://t.co/MnefRxYqMh https://t.co/Mwq4s7eTKY
Dr. John Cush RheumNow ( View Tweet)
Setting a standard for imaging reporting in patients with suspected axial spondyloarthritis is an important part of our efforts toward improving the early and accurate diagnosis of SpA:
https://t.co/zYbcL1CaTP https://t.co/1jnBDBSDNv
Links:
Prof. Denis Poddubnyy DrPoddubnyy ( View Tweet)
Recommendation for management of fatigue in people with rheumatic disease.
Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it.
I will also add yearly blood work including:
1- VitD
2-HBA1c and LDl
3-TsH. https://t.co/3QvPqMxZSN
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
500+ pts AxSPA
No difference in drug discontinuation between IL-17i, TNFi, IL23i over time
Adjusted for CRP, co-medication w/ MTX + classic covariates
IL-17i and IL-23i had experienced a higher number bDMARD failures
#EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca
Aurelie Najm AurelieRheumo ( View Tweet)
What is the meaning of mechanical stress-induced sacroiliac BMO MRI after childbirth in healthy women?
5yrs follow up MRI study shows:
-decrease in BMO
-1/3 BMO @ 5-year follow-up
-15% ASAS definition of sacroiliitis
-No correlation w/ symptoms
@RheumNow #EULAR24 OP0222
Aurelie Najm AurelieRheumo ( View Tweet)
EFFECTIVENESS & COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPA (TeleSpA-STUDY): PRAGMATIC MULTICENTRE RVT cost effective but no one will ever be examined again especially for pathology outside joints! @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
beautiful work Univ of Qld - rat SpA model bacterial dna into entheses blocked by 23i not 17i @RheumNow #EULAR2024 https://t.co/X9hzkA56d0
Peter Nash drpnash ( View Tweet)
Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9
Dr. John Cush RheumNow ( View Tweet)
#Editors Picks @eular_org @ARD_BMJ @ACR_Journals
Can #rheumatologists effectively #dx of #ankylosing #spondylitis?
👍
552 pts - 1/3 axSpA w high certainty
Certainty of #dx changed over time
2 features
#sacroileitis
good #nSAID response
#EULAR2024 @RheumNow https://t.co/NN3GZTmgn9
Links:
Janet Pope Janetbirdope ( View Tweet)
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.… https://t.co/HrRnoDzSPP https://t.co/Gp1KZmPych
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Extra musculoskeletal manifestations (EMMs) in spondyloarthritis #EULAR2024 OP0085 @RheumNow https://t.co/yRxPmMYLxn
Dr. Antoni Chan synovialjoints ( View Tweet)
